Table 2 characteristic stratified by hepatic fibrosis

Gender(male, %)

105 (84.0)

130 (86.7)

303 (83.5)

0.659

Age, y

51.00 [44.00, 61.00]

51.00 [45.00, 61.00]

51.00 [45.00, 58.00]

0.844

AFP (> 400 ng/mL, %)

46 (36.8)

54 (36.0)

162 (44.6)

0.109

HBeAg (%)

14 (11.2)

24 (16.0)

96 (26.4)

< 0.001

Tumor size, cm

5.80 [4.00, 11.00]

4.75 [3.00, 7.50]

4.00 [2.70, 6.20]

< 0.001

Multiple tumor (%)

1 (0.8)

1 (0.7)

10 (2.8)

0.174

Poorly differentiation, (%)

56 (44.8)

66 (44.0)

178 (49.0)

0.499

G stratification, (%)

< 0.001

  minor

18 (14.4)

12 (8.0)

20 (5.5)

  intermediate

84 (67.2)

62 (41.3)

128 (35.3)

  severe

23 (18.4)

76 (50.7)

215 (59.2)

MVI, (%)

36 (28.8)

33 (22.0)

100 (27.5)

0.349

satellite, (%)

11 (8.8)

16 (10.7)

33 (9.1)

0.829

fatty liver, (%)

28 (22.4)

40 (26.7)

76 (20.9)

0.368

capsule invasion, (%)

56 (44.8)

72 (48.0)

140 (38.6)

0.112

HBV-DNA, (> 2000IU/mL, %)

74 (59.2)

75 (50.0)

190 (52.3)

0.282

PT, s

11.90 [11.30, 12.40]

12.00 [11.40, 12.80]

12.20 [11.70, 13.00]

< 0.001

INR

1.00 [1.00, 1.10]

1.00 [1.00, 1.10]

1.10 [1.00, 1.10]

0.005

RBC, x10⁹/L

4.75 [4.27, 5.11]

4.69 [4.34, 5.01]

4.75 [4.34, 5.12]

0.702

HB, g/L

143.00 [132.00, 154.00]

145.00 [134.00, 155.75]

147.00 [133.50, 155.00]

0.288

PLR(> 101, %)

65 (52.0)

61 (40.7)

120 (33.1)

0.001

NLR(> 2.6, %)

46 (36.8)

53 (35.3)

105 (28.9)

0.16

ALT(> 40 IU/L, %)

51 (40.8)

74 (49.3)

137 (37.7)

0.052

AST(> 40 IU/L, %)

53 (42.4)

58 (38.7)

134 (36.9)

0.552

ALB(≤ 40 g/L, %)

4 (3.2)

8 (5.3)

10 (2.8)

0.342

TBIL(> 28 umol/L, %)

0 (0.0)

6 (4.0)

13 (3.6)

0.089

PLT(≤ 100 × 10⁹/L, %)

19 (15.2)

32 (21.3)

139 (38.3)

< 0.001

FIB-4(> 3.6, %)

26 (20.8)

33 (22.0)

121 (33.3)

0.004